Edaravone - Mitsubishi Tanabe Pharma
Alternative Names: 1-phenyl-3-methyl-5-pyrazolone; Edarabone; MCI-186; MT 1186; Norphenazone; Phenylmethylpyrazolone; RADICAVA; Radicava; RADICAVA ORS; RADICUT; Radicut; Radicut BagLatest Information Update: 20 Jun 2024
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Canada; Mitsubishi Tanabe Pharma Corporation
- Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Amyotrophic lateral sclerosis; Cerebral infarction
- Phase II Stroke
- No development reported Liver disorders
- Discontinued Myocardial ischaemia; Parkinson's disease; Reperfusion injury; Subarachnoid haemorrhage
Most Recent Events
- 17 Jun 2024 Launched for Amyotrophic lateral sclerosis in Puerto Rico (IV) before June 2024
- 17 Jun 2024 Launched for Amyotrophic lateral sclerosis in Puerto Rico (PO) before June 2024
- 17 Jun 2024 Adverse events data from the phase III MT-1186-A03 trial in Amyotrophic lateral sclerosis released by Mitsubishi Tanabe Pharma